Results 91 to 100 of about 24,744 (229)
Metabolic Syndrome: From Mechanisms to Therapeutic Interventions
MedComm, Volume 7, Issue 9, September 2026.A comprehensive overview of molecular mechanisms delves into the potential disease mechanisms of metabolic syndrome, including complex mechanisms such as insulin resistance, chronic low‐grade inflammation, oxidative stress, and epigenetic modifications, and how these mechanisms contribute to the development of metabolic syndrome. Here, the relationship
Mengyao Yan, Qian Xiang
wiley +1 more source
New England Journal of Medicine, 2004 Derek Grubb, JR Greenfield, DJ Chisholm
openaire +3 more sources
The role of pharmacogenetics in the treatment of diabetes mellitus [PDF]
Journal of Medical Biochemistry, 2014 Diabetes mellitus is a heterogeneous group of disorders in which particular disease phenotypes can be characterized by a specific etiology and/or pathogenesis of the disease, but in many cases its classification is greatly impeded due to significant ...
Topić Elizabeta
doaj
Proteins: Structure, Function, and Bioinformatics, Volume 94, Issue 9, Page 1597-1609, September 2026.ABSTRACT Post‐translational modifications (PTMs) play a critical role in regulating the transcriptional activity of PPARγ, a nuclear receptor central to glucose and lipid homeostasis. Among these, lysine acetylation at K268 and K293 and phosphorylation at S273 are particularly relevant to insulin sensitivity.
Caique Camargo Malospirito +6 more
wiley +1 more source
ChemistrySelect, Volume 11, Issue 33, 1 September 2026.This narrative review analyzes DENV molecular targets, including structural proteins (C, prM/M, E), non‐structural components (NS1NS5), and host factors, alongside small‐molecule candidates in preclinical and clinical phases. Owing to high structural conservation, the NS2B‐NS3 protease and NS5 (RdRp/MTase) remain primary drug discovery focuses, while ...
Aryane Lucia da Silva Aguiar De Oliveira +8 more
wiley +1 more source
Annals of Human Genetics, Volume 90, Issue 5, Page 294-302, September 2026.ABSTRACT Aims There is no proven treatment to prevent the growth or rupture of abdominal aortic aneurysm (AAA). As an aneurysm enlarges over time, the risk of fatal aortic rupture increases. Metformin, a drug usually prescribed to treat Type 2 diabetes, has previously been associated with reduced AAA risk in observational studies. Our aim was to assess
Katie Louise Saxby +5 more
wiley +1 more source
Sexual Safety Signals of Common Antidiabetic Drugs: Insights From FAERS Disproportionality Analysis
Andrology, Volume 14, Issue 6, Page 1627-1635, September 2026.ABSTRACT Background Erectile dysfunction is a prevalent and distressing complication of diabetes mellitus that markedly affects quality of life in male patients. Although the role of diabetes in erectile dysfunction is well‐established, potential drug‐induced sexual dysfunction associated with commonly prescribed antidiabetic medications remains ...
Shan Lin +3 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 7791-7801, September 2026.ABSTRACT Aims ONWARDS 10 assessed switching from daily basal insulins to once‐weekly insulin icodec without a one‐time additional dose at first injection. Materials and Methods In this treat‐to‐target, open‐label, 26‐week, phase 3b trial, adults with basal‐insulin‐treated type 2 diabetes (T2D) with glycated haemoglobin [HbA1c] 7.0%–10.0% were ...
Julio Rosenstock +5 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 7950-7963, September 2026.ABSTRACT Aims Sodium–glucose co‐transporter 2 inhibitors (SGLT2is) and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have separately shown renoprotective effects in clinical trials in people with type 2 diabetes. It is unclear whether combining these agents produces incremental kidney outcome benefits. Materials and Methods Retrospective cohort
William Hinton +11 more
wiley +1 more source
Prescribing Trajectories in Type 2 Diabetes in the United States, 2019–2024
Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8172-8188, September 2026.ABSTRACT Importance Clinical guidelines for type 2 diabetes (T2D) provide population‐level recommendations, but real‐world treatment patterns evolve dynamically and vary across patients. Understanding longitudinal prescribing trajectories may reveal heterogeneity in care not captured by cross‐sectional analyses.
Tobias S. Lux +14 more
wiley +1 more source